Gold prices slip after rallying on Powell rate cut talk
Carl Dambkowski, the Chief Medical (TASE:BLWV) Officer of Apogee (NASDAQ:APOG) Therapeutics, Inc. (NASDAQ:APGE), a $2.06 billion market cap biotech company, recently sold shares of the company’s common stock. According to InvestingPro data, the stock has shown strong momentum with a 15% gain over the past week. According to a filing with the Securities and Exchange Commission, Dambkowski sold 1,590 shares on March 5, 2025, at a price of $30.48 each, totaling $48,463. This transaction was executed under a Rule 10b5-1 trading plan adopted on August 21, 2024. Following this sale, Dambkowski retains ownership of 251,033 shares in the company. The company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 18.5x, though analysts anticipate continued losses this year.
In other recent news, Apogee Therapeutics has seen significant developments. Jefferies analyst Akash Tewari has raised the price target for Apogee Therapeutics to $86, up from $82, while maintaining a Buy rating. This adjustment follows promising data from the company’s early-stage clinical trials, particularly in their Phase 1b trial for Atopic Dermatitis. The trials are exploring the IL13/OX40L combination therapy, with data expected in the second half of 2026. Furthermore, Apogee’s drug APG990 has shown positive outcomes in a Single Ascending Dose study, which has contributed to a revised valuation of $1.8 billion for the drug. Meanwhile, Guggenheim has reaffirmed its Buy rating for Apogee, citing recent clinical trial failures by competitors in the atopic dermatitis market. These setbacks for competitors highlight Apogee’s focus on clinically validated monoclonal antibodies and rigorous trial design. Guggenheim’s confidence in Apogee is bolstered by the reduced competition and the company’s strategic positioning in a market projected to grow significantly.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.